0001104659-22-007832.txt : 20220126 0001104659-22-007832.hdr.sgml : 20220126 20220126161547 ACCESSION NUMBER: 0001104659-22-007832 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220120 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220126 DATE AS OF CHANGE: 20220126 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Eucrates Biomedical Acquisition Corp. CENTRAL INDEX KEY: 0001822929 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 000000000 STATE OF INCORPORATION: D8 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39650 FILM NUMBER: 22558076 BUSINESS ADDRESS: STREET 1: 250 WEST 55TH STREET, SUITE 13D CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: (212) 710-5220 MAIL ADDRESS: STREET 1: 250 WEST 55TH STREET, SUITE 13D CITY: NEW YORK STATE: NY ZIP: 10019 8-K 1 tm224508d1_8k.htm FORM 8-K
0001822929 false 00-0000000 0001822929 2022-01-20 2022-01-20 0001822929 eucr:UnitseachconsistingofoneordinarysharenoparvalueandonethirdofoneWarrantMember 2022-01-20 2022-01-20 0001822929 eucr:OrdinarySharesnoparvalueMember 2022-01-20 2022-01-20 0001822929 us-gaap:WarrantMember 2022-01-20 2022-01-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): January 20, 2022

 

Eucrates Biomedical Acquisition Corp.

(Exact name of registrant as specified in its charter)

 

 

 

British Virgin Islands   001-39650   N/A
(State or other jurisdiction   (Commission   (I.R.S. Employer
of incorporation)   File Number)   Identification No.)

 

250 West 55th Street, Suite 13D    
New York, NY   10019
(Address of principal executive offices)   (Zip Code)

 

(212) 710-5220

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨       Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨       Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨       Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨       Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

 

Title of each class  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Units, each consisting of one ordinary share, no par value, and one-third of one Warrant   EUCRU   Nasdaq Capital Market
Ordinary shares, no par value   EUCR   Nasdaq Capital Market
Warrants, each whole warrant exercisable for one ordinary share at an exercise price of $11.50 per share   EUCRW   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 1.01. Entry into a Material Definitive Agreement.

 

On January 20, 2022, Eucrates Biomedical Acquisition Corp. (the “Company”) issued an unsecured promissory note (the “Promissory Note”) to Eucrates LLC (the “Sponsor”). The Promissory Note provides that the Company may borrow up to an aggregate maximum amount of $600,000 from the Sponsor. On January 24, 2022, the Company made an initial draw on the Promissory Note of $250,000. Amounts up to the aggregate maximum amount may and are expected to be drawn down from time to time by the Company pursuant to the Promissory Note to fund its working capital requirements and for general corporate purposes. The Promissory Note does not bear any interest. If the Company completes an initial business combination, the Company would repay outstanding loaned amounts under the Promissory Note. In the event that the Company is unable to complete an initial business combination, the Company may use a portion of the working capital held outside its trust account to repay such loaned amounts but no proceeds from its trust account would be used for such repayment. The loans are convertible into units of the Company, at a price of $10.00 per unit, at the option of the Sponsor. The units would be identical to those units that were issued to the Sponsor in a private placement concurrent with the Company’s initial public offering.

 

The foregoing summary of the Promissory Note is qualified in its entirety by reference to the text of the Promissory Note, which is filed as exhibit 10.1 hereto and incorporated by reference herein.

 

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

 

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.

 

Item 3.02 Unregistered Sales of Equity Securities

 

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.02. An aggregate of 60,000 private placement units of the Company would be issued if the entire aggregate amount of the Promissory Note is drawn and subsequently converted. Each unit would consist of one ordinary share of the Company and one-third of one warrant exercisable for one ordinary share of the Company. The warrants included in the private placement units would be exercisable, subject to the terms and conditions of the warrant and during the exercise period as provided in the warrant agreement governing the warrants. The Company has relied upon Section 4(a)(2) of the Securities Act of 1933, as amended, in connection with the issuance and sale of the Promissory Note.

 

Item 9.01 Financial Statements and Exhibits.

 

Exhibit No.   Description
10.2   Promissory Note, dated January 20, 2022
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

EUCRATES BIOMEDICAL ACQUISITION CORP.
  
Date: January 26, 2022/s/ Gonzalo Cordova
 Name: Gonzalo Cordova
 Title: Chief Financial Officer

 

 

 EX-10.2 2 tm224508d1_ex10-2.htm EXHIBIT 10.2

 

Exhibit 10.2

 

THIS PROMISSORY NOTE (“NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE SALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY DESIGNATED BELOW THAT SUCH REGISTRATION IS NOT REQUIRED.

 

PROMISSORY NOTE

 

Principal Amount: Up to $600,000 Dated as of January 20, 2022
  New York, New York

 

Eucrates Biomedical Acquisition Corp., a British Virgin Islands company (the “Company”), promises to pay to the order of Eucrates LLC or its registered assigns or successors in interest (the “Payee”), or order, the principal sum of up to Six Hundred Thousand Dollars ($600,000) in lawful money of the United States of America, on the terms and conditions described below. All payments on this Note shall be made by check or wire transfer of immediately available funds or as otherwise determined by the Company to such account as the Payee may from time to time designate by written notice in accordance with the provisions of this Note.

 

1.            Principal. The principal balance of this Note shall be payable by the Company on the earliest to occur of (i) the date on which Company consummates its initial business combination, (ii) the date that the winding up of the Company is effective (such date, the “Maturity Date”). The principal balance may be prepaid at any time without premium or penalty. Under no circumstances shall any individual, including but not limited to any officer, director, employee or stockholder of the Company, be obligated personally for any obligations or liabilities of the Company hereunder.

 

2.            Interest. No interest shall accrue on the unpaid principal balance of this Note.

 

3.            Drawdown Requests. Company and Payee agree that Company may request up to Six Hundred Thousand Dollars ($600,000) for costs reasonably related to working capital and general corporate purposes. The principal of this Note may be drawn down from time to time prior to the Maturity Date, upon written request from Company to Payee (each, a “Drawdown Request”). Each Drawdown Request must state the amount to be drawn down, and must not be an amount less than Ten Thousand Dollars ($10,000). Payee shall fund each Drawdown Request no later than five (5) business days after receipt of a Drawdown Request; provided, however, that the maximum amount of drawdowns under this Note is Six Hundred Thousand Dollars ($600,000). Once an amount is drawn down under this Note, it shall not be available for future Drawdown Requests even if any portion of the principal balance is prepaid. No fees, payments or other amounts shall be due to Payee in connection with, or as a result of, any Drawdown Request by Company. Notwithstanding the foregoing, all payments and prepayments by the Company shall be applied first to payment in full of any costs incurred in collection of any sum due under this Note, including (without limitation) reasonable attorneys' fees, and then to the reduction of the unpaid principal balance of this Note.

 

4.             Representations and Warranties. Company represents and warrants to Payee on the date hereof as follows:

 

(a)       Existence. Company is a corporation duly incorporated, validly existing and in good standing under the laws of the state of its jurisdiction of organization.

 

 

 

 

(b)       Power and Authority. Company has the power and authority, and the legal right, to execute and deliver this Note and to perform its obligations hereunder.

 

(c)       Authorization; Execution and Delivery. The execution and delivery of this Note by Company and the performance of its obligations hereunder have been duly authorized by all necessary corporate action in accordance with all applicable laws. The Company has duly executed and delivered this Note.

 

(d)       No Approvals. No consent or authorization of, filing with, notice to or other act by, or in respect of, any governmental authority is required in order for Company to execute, deliver, or perform any of its obligations under this Note.

 

(e)       No Violations. The execution and delivery of this Note and the consummation by the Company of the transactions contemplated hereby do not and will not (a) violate any provision of Company's organizational documents; (b) violate any law applicable to the Company or by which any of its properties or assets may be bound; or (c) constitute a default under any material agreement or contract by which Company may be bound.

 

(f)        Enforceability. The Note is a valid, legal and binding obligation of Company, enforceable against the Company in accordance with its terms except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of creditors’ rights generally and by general equitable principles (whether enforcement is sought by proceedings in equity or at law).

 

5.             Events of Default. Each of the following shall constitute an event of default (“Event of Default”):

 

(a)       Failure to Make Required Payments. Failure by Company to pay the outstanding balance due pursuant to this Note within five (5) business days of the Maturity Date.

 

(b)       Voluntary Bankruptcy. Etc. The commencement by Company of a voluntary case under any applicable bankruptcy, insolvency, reorganization, rehabilitation or other similar law, or the consent by it to the appointment of or taking possession by a receiver, liquidator, assignee, trustee, custodian, sequestrator (or other similar official) of Company or for any substantial part of its property, or the making by it of any assignment for the benefit of creditors, or the failure of Company generally to pay its debts as such debts become due, or the taking of corporate action by Company in furtherance of any of the foregoing.

 

(c)       Involuntary Bankruptcy, Etc. The entry of a decree or order for relief by a court having jurisdiction in the premises in respect of Company in an involuntary case under any applicable bankruptcy, insolvency, reorganization, rehabilitation or other similar law, or appointing a receiver, liquidator, assignee, custodian, trustee, sequestrator (or other similar official) of Company or for any substantial part of its property, or ordering the winding-up or liquidation of its affairs, and the continuance of any such decree or order un stayed and in effect for a period of 60 consecutive days.

 

6.             Remedies.

 

(a)        Upon the occurrence of an Event of Default specified in Section 5(a) hereof, Payee may, by written notice to Company, declare this Note to be due immediately and payable, whereupon the outstanding balance of this Note, and all other amounts payable hereunder, shall become immediately due and payable without presentment, demand, protest or other notice of any kind, all of which are hereby expressly waived, anything contained herein or in the documents evidencing the same to the contrary notwithstanding.

 

 

 

 

(b)        Upon the occurrence of an Event of Default specified in Sections 5(b) and 5(c), the unpaid principal balance of this Note, and all other amounts payable hereunder, shall automatically and immediately become due and payable, in all cases without any action on the part of Payee.

 

7.            Waivers. Company and all endorsers and guarantors of, and sureties for, this Note waive presentment for payment, demand, notice of dishonor and notice of protest with regard to this Note, all errors, defects and imperfections in any proceedings instituted by Payee under the terms of this Note, and all benefits that might accrue to Company by virtue of any present or future laws exempting any property, real or personal, or any part of the proceeds arising from any sale of any such property, from attachment, levy or sale under execution, or providing for any stay of execution, exemption from civil process, or extension of time for payment; and Company agrees that any real estate that may be levied upon pursuant to a judgment obtained by virtue hereof, or any writ of execution issued hereon, may be sold upon any such writ in whole or in part in any order desired by Payee.

 

8.            Unconditional Liability. Company hereby waives all notices in connection with the delivery, acceptance, performance, default, or enforcement of the payment of this Note, and agrees that its liability shall be unconditional, without regard to the liability of any other party, and shall not be affected in any manner by any indulgence, extension of time, renewal, waiver or modification granted or consented to by Payee, and consents to any and all extensions of time, renewals, waivers, or modifications that may be granted by Payee with respect to the payment or other provisions of this Note, and agrees that additional makers, endorsers, guarantors, or sureties may become parties hereto without notice to Company or affecting Company’s liability hereunder.

 

9.            Notices. All notices, statements or other documents which are required or contemplated by this Note shall be made in writing and delivered (i) personally or sent by first class registered or certified mail, or overnight courier service, to the address most recently provided to such party or such other address as may be designated in writing by such party, (ii) by facsimile to the number most recently provided to such party or such other fax number as may be designated in writing by such party or (iii) by electronic mail, to the electronic mail address most recently provided to such party or such other electronic mail address as may be designated in writing by such party. Any notice or other communication so transmitted shall be deemed to have been given on the day of delivery, if delivered personally, on the business day following receipt of written confirmation, if sent by facsimile or electronic transmission, one (1) business day after delivery to an overnight courier service or five (5) days after mailing if sent by mail.

 

10.            Governing Law; Construction; Jurisdiction. This Note shall be governed by and construed and enforced in accordance with the laws of the State of New York, without giving effect to conflicts of law principles that would result in the application of the substantive laws of another jurisdiction. The parties hereto (i) agree that any action, proceeding, claim or dispute arising out of, or relating in any way to, this Note shall be brought and enforced in the courts of New York, in the State of New York, and irrevocably submit to such jurisdiction and venue, which jurisdiction and venue shall be exclusive and (ii) waive any objection to such exclusive jurisdiction and venue or that such courts represent an inconvenient forum.

 

11.            Severability. Any provision contained in this Note which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.

 

 

 

 

12.            Trust Waiver. Payee hereby irrevocably waives any and all right, title, interest, causes of action and claims of any kind or nature whatsoever (each, a “Claim”) in or to, and any and all right to seek payment of any amounts due to it out of, the trust account established for the benefit of the public stockholders of the Company and into which substantially all of the proceeds of the Company’s initial public offering have been deposited (the “Trust Account”), and hereby irrevocably waives any Claim it presently has or may have in the future as a result of, or arising out of, this agreement, which Claim would reduce, encumber or otherwise adversely affect the Trust Account or any monies or other assets in the Trust Account, and further agrees not to seek recourse, reimbursement, payment or satisfaction of any Claim against the Trust Account or any monies or other assets in the Trust Account for any reason whatsoever.

 

13.            Amendment; Waiver. Any amendment hereto or waiver of any provision hereof may be made with, and only with, the written consent of the Company and the Payee.

 

14.           Assignment. No assignment or transfer of this Note or any rights or obligations hereunder may be made by any party hereto (by operation of law or otherwise) without the prior written consent of the other party hereto and any attempted assignment without the required consent shall be void.

 

15.           Conversion.

 

(a)        Notwithstanding anything contained in this Note to the contrary, at Payee’s option, at any time prior to payment in full of the principal balance of this Note, Payee may elect to convert all or any portion of the unpaid principal balance of this Note into that number of units, each unit consisting of one ordinary share of the Company and one-third of one warrant exercisable for one ordinary share of the Company (the “Conversion Units”), equal to: (x) the portion of the principal amount of this Note being converted pursuant to this Section 15, divided by (y) $10.00, rounded up to the nearest whole number of units. The Conversion Units shall be identical to the units issued by the Company to the Payee in a private placement upon consummation of the Company’s initial public offering. The Conversion Units and their underlying securities, and any other equity security of the Company issued or issuable with respect to the foregoing by way of a stock dividend or stock split or in connection with a combination of shares, recapitalization, amalgamation, consolidation or reorganization, shall be entitled to the registration rights set forth in Section 16 hereof.

 

(b)        Upon any complete or partial conversion of the principal amount of this Note, (i) such principal amount shall be so converted and such converted portion of this Note shall become fully paid and satisfied, (ii) Payee shall surrender and deliver this Note, duly endorsed, to the Company or such other address which the Company shall designate against delivery of the Conversion Units, (iii) the Company shall promptly deliver a new duly executed Note to Payee in the principal amount that remains outstanding, if any, after any such conversion and (iv) in exchange for all or any portion of the surrendered Note, the Company shall, at the direction of Payee, deliver to Payee (or its members or their respective affiliates) (Payee or such other persons, the “Holders”) the Conversion Units, which shall bear such legends as are required, in the opinion of counsel to the Company or by any other agreement between the Company and Payee and applicable state and federal securities laws.

 

(c)        The Holders shall pay any and all issue and other taxes that may be payable with respect to any issue or delivery of the Conversion Units upon conversion of this Note pursuant hereto; provided, however, that the Holders shall not be obligated to pay any transfer taxes resulting from any transfer requested by the Holders in connection with any such conversion.

 

 

 

 

(d)        The Conversion Units shall not be issued upon conversion of this Note unless such issuance and such conversion comply with all applicable provisions of law.

 

15.           Registration Rights.

 

(a)        Reference is made to that certain Registration Rights Agreement between the Company and the parties thereto, dated as of October 23, 2020 (the “Registration Rights Agreement”). All capitalized terms used in this Section 16 shall have the same meanings ascribed to them in the Registration Rights Agreement.

 

(b)        The Holders shall be entitled to one Demand Registration, which shall be subject to the same provisions as set forth in Section 2.1 of the Registration Rights Agreement.

 

(c)        The Holders shall also be entitled to include the Conversion Units and their underlying securities in Piggyback Registrations, which shall be subject to the same provisions as set forth in Section 2.2 of the Registration Rights Agreement; provided, however, that in the event that an underwriter advises the Company that the Maximum Number of Securities has been exceeded with respect to a Piggyback Registration, the Holders shall not have any priority for inclusion in such Piggyback Registration.

 

(d)        Except as set forth above, the Holders and the Company, as applicable, shall have all of the same rights, duties and obligations set forth in the Registration Rights Agreement.

 

[Signature Page Follows]

 

 

 

 

IN WITNESS WHEREOF, the Company, intending to be legally bound hereby, has caused this Note to be duly executed by the undersigned as of the day and year first above written.

 

 

  EUCRATES BIOMEDICAL ACQUISITION CORP.
       
       
  By: /s/ Parag Saxena                                        
    Name: Parag Saxena
    Title: Chief Executive Officer
       
       
  By: /s/ Gonzalo Cordova                                   
    Name: Gonzalo Cordova
    Title: Chief Financial Officer

 

 

Payee hereby acknowledges and agrees to the foregoing as of the date first written above.

 

ACKNOWLEDGED AND ACCEPTED

  

 

EUCRATES LLC
       
       
By: /s/ Parag Saxena                                  
  Name: Parag Saxena  
  Title: Managing Member  
       
       
By: /s/ Stelios Papadopoulos                                  
  Name: Stelios Papadopoulos  
  Title: Managing Member  

  

 

 

 

 EX-101.SCH 3 eucr-20220120.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 eucr-20220120_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 eucr-20220120_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Units, each consisting of one ordinary share, no par value, and one-third of one Warrant [Member] Ordinary shares, no par value [Member] Warrant [Member] Statement [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Ordinary shares, no par value [Member] Units, each consisting of one ordinary share, no par value, and one-third of one Warrant [Member] EX-101.PRE 6 eucr-20220120_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.4
Cover
Jan. 20, 2022
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 20, 2022
Entity File Number 001-39650
Entity Registrant Name Eucrates Biomedical Acquisition Corp.
Entity Central Index Key 0001822929
Entity Tax Identification Number 00-0000000
Entity Incorporation, State or Country Code D8
Entity Address, Address Line One 250 West 55th Street
Entity Address, Address Line Two Suite 13D
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10019
City Area Code 212
Local Phone Number 710-5220
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Units, each consisting of one ordinary share, no par value, and one-third of one Warrant [Member]  
Document Information [Line Items]  
Title of 12(b) Security Units, each consisting of one ordinary share, no par value, and one-third of one Warrant
Trading Symbol EUCRU
Security Exchange Name NASDAQ
Ordinary shares, no par value [Member]  
Document Information [Line Items]  
Title of 12(b) Security Ordinary shares, no par value
Trading Symbol EUCR
Security Exchange Name NASDAQ
Warrant [Member]  
Document Information [Line Items]  
Title of 12(b) Security Warrants, each whole warrant exercisable for one ordinary share at an exercise price of $11.50 per share
Trading Symbol EUCRW
Security Exchange Name NASDAQ
XML 8 tm224508d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001822929 2022-01-20 2022-01-20 0001822929 eucr:UnitseachconsistingofoneordinarysharenoparvalueandonethirdofoneWarrantMember 2022-01-20 2022-01-20 0001822929 eucr:OrdinarySharesnoparvalueMember 2022-01-20 2022-01-20 0001822929 us-gaap:WarrantMember 2022-01-20 2022-01-20 iso4217:USD shares iso4217:USD shares 0001822929 false 00-0000000 8-K 2022-01-20 Eucrates Biomedical Acquisition Corp. D8 001-39650 250 West 55th Street Suite 13D New York NY 10019 212 710-5220 false false false false Units, each consisting of one ordinary share, no par value, and one-third of one Warrant EUCRU NASDAQ Ordinary shares, no par value EUCR NASDAQ Warrants, each whole warrant exercisable for one ordinary share at an exercise price of $11.50 per share EUCRW NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 4 122 1 false 3 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://eucrates.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm224508d1_8k.htm eucr-20220120.xsd eucr-20220120_def.xml eucr-20220120_lab.xml eucr-20220120_pre.xml tm224508d1_ex10-2.htm http://xbrl.sec.gov/dei/2021q4 http://fasb.org/us-gaap/2021-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm224508d1_8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 4, "dts": { "definitionLink": { "local": [ "eucr-20220120_def.xml" ] }, "inline": { "local": [ "tm224508d1_8k.htm" ] }, "labelLink": { "local": [ "eucr-20220120_lab.xml" ] }, "presentationLink": { "local": [ "eucr-20220120_pre.xml" ] }, "schema": { "local": [ "eucr-20220120.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" ] } }, "elementCount": 66, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 122, "memberCustom": 2, "memberStandard": 1, "nsprefix": "eucr", "nsuri": "http://eucrates.com/20220120", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm224508d1_8k.htm", "contextRef": "From2022-01-20to2022-01-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://eucrates.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm224508d1_8k.htm", "contextRef": "From2022-01-20to2022-01-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "booleanItemType" }, "eucr_OrdinarySharesnoparvalueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ordinary shares, no par value [Member]", "label": "Ordinary shares, no par value [Member]" } } }, "localname": "OrdinarySharesnoparvalueMember", "nsuri": "http://eucrates.com/20220120", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "domainItemType" }, "eucr_UnitseachconsistingofoneordinarysharenoparvalueandonethirdofoneWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Units, each consisting of one ordinary share, no par value, and one-third of one Warrant [Member]", "label": "Units, each consisting of one ordinary share, no par value, and one-third of one Warrant [Member]" } } }, "localname": "UnitseachconsistingofoneordinarysharenoparvalueandonethirdofoneWarrantMember", "nsuri": "http://eucrates.com/20220120", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://eucrates.com/role/Cover" ], "xbrltype": "domainItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001104659-22-007832-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-007832-xbrl.zip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�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end